Ready for a strong start in oligonucleotide manufacturing?
If you’re developing an antisense oligonucleotides (ASOs), siRNA, or other oligonucleotide therapeutic, you’re already aware of the promise these molecules have. So how can you harness this potential? The first step is knowing where to focus in the early stages of process development for oligonucleotide therapeutics. Choices you make now can have huge impacts later on. This includes speed to market, regulatory acceptance, manufacturing costs, and achieving process sustainability at large scale. A strong technology provider should be able to support you in meeting your goals. Learn more about how to enter oligonucleotide manufacturing and how Cytiva can support you.
Oligonucleotide therapeutics have huge potential for transforming human health. If you’re a small biotech or lab developing such therapies, playing the long game is crucial to successful in-house manufacturing. Here are 5 tips to get a strong start.
Cytiva launched ӒKTA oligosynt™ benchtop oligo synthesizer in 2022 and it forms part of this research scale workflow.
The oligonucleotide synthesis process consists of a repetitive four-step cycle. This animation explains how this cycle works.
In this free e-learning you can learn about synthetic oligonucleotides, what their building blocks are, gain knowledge in the cyclic synthesis process, the solid support on which this takes place and learn about how to purify the synthesized oligonucleotides.
An educational walk-through of the key components and functions of the ÄKTA oligosynt™ synthesizer.
Building on 40 years of experience, Cytiva launched ӒKTA oligosynt™ benchtop oligo synthesizer in 2022. We have a family of oligo systems that scales from 10 μmol to 1800 mmol. This flier will help you choose which oligo synthesizer is right for you.
Do you want to learn more about the ӒKTA oligosynt™ benchtop oligo synthesizer that Cytiva launched in 2022? Everything you need to know is in this product data file.
At Cytiva, our mission is to advance and accelerate the development of therapeutics. With nearly 16 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma, and contract manufacturers. Learn more at cytiva.com.
Unlock the power of oligonucleotide therapeutics with the confidence that comes from working a strong technology provider. At Cytiva we have the depth of prior knowledge and process experience that can really make a difference in the development of your oligonucleotide process and scale-up.